© 2021 MJH Life Sciences and Pharmacy Times. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmacy Times. All rights reserved.
July 22, 2019
On July 20, 2018, the FDA approved ivosidenib (Tibsovo) as a treatment option for adult patients with relapsed/refractory acute myeloid leukemia, specifically with a mutation in the IDH1 gene.
May 16, 2019
On July 20, 2018, Pfizer Inc announced the FDA approval of filgrastim-aafi (Nivestym), a biosimilar to Amgenâ€™s biologic Neupogen (filgrastim).
April 17, 2019
Accreditation helps pharmaceutical manufacturers narrow the potential pharmacies it may include in a specialty network offering.
March 15, 2019
Celgene Corporationâ€™s lenalidomide (Revlimid) is a targeted therapy that stops the growth of myeloma cells in the bone marrow.